Advertisement

 

 

Incretin-based glucose-lowering medications and the risk for acute pancreatitis and/or pancreatic cancer risk: Reassuring data from cardio-vascular outcome trials.

Incretin-based glucose-lowering medications and the risk for acute pancreatitis and/or pancreatic cancer risk: Reassuring data from cardio-vascular outcome trials.
Author Information (click to view)

Nauck MA, Meier JJ, Schmidt WE,


Nauck MA, Meier JJ, Schmidt WE, (click to view)

Nauck MA, Meier JJ, Schmidt WE,

Advertisement

Diabetes, obesity & metabolism 2017 04 22() doi 10.1111/dom.12981
Abstract

Incretin-based medications (glucagon-like peptide-1 [GLP-1] receptor agonists and inhibitors of dipeptidyl peptidase-4 [DPP-4] are glucose-lowering drugs approved and introduced after 2006 (1). Although both classes of drugs appeared to be relatively safe based on results from clinical trials and standard animal toxicology studies, epidemiological data (2, 3) and histological findings (4) in genetically modified rodents exposed to such agents have raised concern that pancreatitis and pancreatic cancer may be long-term risks associated with this therapy.

Submit a Comment

Your email address will not be published. Required fields are marked *

18 − thirteen =

[ HIDE/SHOW ]